Atria Investments Inc Takes $323,000 Position in Ionis Pharmaceuticals, Inc. $IONS

Atria Investments Inc acquired a new position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) in the second quarter, HoldingsChannel reports. The fund acquired 8,186 shares of the company’s stock, valued at approximately $323,000.

Other large investors have also made changes to their positions in the company. IQ EQ FUND MANAGEMENT IRELAND Ltd grew its position in Ionis Pharmaceuticals by 64.6% during the second quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 13,263 shares of the company’s stock valued at $524,000 after acquiring an additional 5,204 shares during the period. Teacher Retirement System of Texas lifted its stake in shares of Ionis Pharmaceuticals by 33.5% in the 2nd quarter. Teacher Retirement System of Texas now owns 668,273 shares of the company’s stock valued at $26,403,000 after purchasing an additional 167,822 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of Ionis Pharmaceuticals in the 2nd quarter valued at about $1,488,000. TD Asset Management Inc grew its holdings in shares of Ionis Pharmaceuticals by 0.4% during the 2nd quarter. TD Asset Management Inc now owns 1,104,690 shares of the company’s stock worth $43,646,000 after purchasing an additional 4,224 shares during the period. Finally, Vanguard Personalized Indexing Management LLC increased its position in Ionis Pharmaceuticals by 17.1% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 12,072 shares of the company’s stock worth $477,000 after purchasing an additional 1,759 shares in the last quarter. 93.86% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, Director Joseph H. Wender sold 11,200 shares of the stock in a transaction on Friday, October 31st. The shares were sold at an average price of $75.16, for a total transaction of $841,792.00. Following the transaction, the director directly owned 64,035 shares in the company, valued at $4,812,870.60. This represents a 14.89% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director B Lynne Parshall sold 5,000 shares of the firm’s stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $71.74, for a total transaction of $358,700.00. Following the transaction, the director directly owned 61,344 shares of the company’s stock, valued at approximately $4,400,818.56. This represents a 7.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 924,789 shares of company stock valued at $59,515,499 over the last ninety days. 2.71% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. TD Cowen boosted their price objective on shares of Ionis Pharmaceuticals from $59.00 to $99.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. BMO Capital Markets upgraded Ionis Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $40.00 to $70.00 in a research note on Wednesday, September 3rd. Guggenheim increased their target price on Ionis Pharmaceuticals from $90.00 to $92.00 and gave the company a “buy” rating in a research note on Tuesday, September 23rd. Royal Bank Of Canada raised their target price on Ionis Pharmaceuticals from $80.00 to $82.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. Finally, Raymond James Financial restated a “strong-buy” rating and issued a $89.00 price target (up previously from $85.00) on shares of Ionis Pharmaceuticals in a report on Thursday, October 30th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Ionis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $84.15.

Ionis Pharmaceuticals Trading Up 4.2%

Shares of IONS opened at $72.45 on Wednesday. Ionis Pharmaceuticals, Inc. has a one year low of $23.95 and a one year high of $76.78. The stock has a 50-day moving average price of $67.95 and a 200 day moving average price of $48.95. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.86 and a current ratio of 2.87. The company has a market capitalization of $11.74 billion, a P/E ratio of -42.87 and a beta of 0.33.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its earnings results on Wednesday, October 29th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.35. The company had revenue of $157.00 million for the quarter, compared to analyst estimates of $131.75 million. Ionis Pharmaceuticals had a negative return on equity of 45.29% and a negative net margin of 26.45%.Ionis Pharmaceuticals’s quarterly revenue was up 17.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.95) EPS. Ionis Pharmaceuticals has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current fiscal year.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.